Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The effect of administering a crushed prasugrel loading dose is uncertain in patients presenting with a large myocardial infarction and ST-segment elevation myocardial infarction (STEMI).
Aims: The aim of this study was to investigate if patients with a large myocardial infarction may benefit from prehospital administration of a crushed prasugrel loading dose.
Methods: Patients from the CompareCrush trial with an available ambulance electrocardiography (ECG) were included in the study. An independent core laboratory confirmed a prehospital large myocardial area. We compared pre- and postprocedural angiographic markers, including Thrombolysis in Myocardial Infarction (TIMI) 3 flow in the infarct-related artery, high thrombus burden, and myocardial blush grade 3, in STEMI patients with and without a prehospital large myocardial area.
Results: Ambulance ECG was available for 532 patients, of whom 331 patients were identified with a prehospital large myocardial area at risk. Crushed prasugrel significantly improved postprocedural TIMI 3 flow rates in STEMI patients with a prehospital large myocardial area at risk (92% vs 79%, odds ratio [OR] 3.00, 95% confidence interval [CI]: 1.50-6.00) but not in STEMI patients without a prehospital large myocardial area at risk (91% vs 95%, OR 0.47, 95% CI: 0.14-1.57; p=0.009).
Conclusions: Administration of crushed prasugrel may improve postprocedural TIMI 3 flow in STEMI patients with signs of a large myocardial area at risk on the ambulance ECG. The practice of crushing tablets of prasugrel loading dose might, therefore, represent a safe, fast and cost-effective strategy to improve myocardial reperfusion in this high-risk STEMI subgroup undergoing primary percutaneous coronary intervention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10979386 | PMC |
| http://dx.doi.org/10.4244/EIJ-D-23-00618 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk prediction of mechanical complications in acute myocardial infarction patients with prior malignancy.
Front Pharmacol
August 2025
Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background: Acute myocardial infarction (AMI) patients with prior malignancy have been largely understudied, despite potentially facing higher risks of adverse outcomes. This case-control study aimed to identify independent risk factors for in-hospital mechanical complications among AMI patients with prior malignancies.
Methods: This study enrolled AMI patients with prior malignancy who were hospitalized for treatment.
Enhanced ISGylation via USP18 Isopeptidase Inactivation Fails to Mitigate the Inflammatory or Functional Course of Coxsackievirus B3-Induced Myocarditis.
Cell Physiol Biochem
September 2025
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, 10117 Berlin, Germany.
Background/aims: The ubiquitin-like protein ISG15 and its covalent conjugation to substrates (ISGylation) represent a critical interferon (IFN)-induced antiviral mechanism. USP18 is an ISG15-specific isopeptidase and a key negative regulator of type I IFN signaling. While inactivation of USP18's catalytic activity enhances ISGylation and promotes viral resistance, its role in modulating inflammation and cardiac function during CVB3-induced myocarditis remains unclear.
View Article and Find Full Text PDFPrediction of in-hospital mortality in patients with acute myocardial infarction following primary percutaneous coronary intervention: A machine learning approach.
Heart Lung
September 2025
Department of Nursing, College of Medicine, National Cheng Kung University, No. 1, University Road, East District, Tainan City 70101, Taiwan. Electronic address:
Background: In-hospital mortality in patients with acute myocardial infarction (AMI) following primary percutaneous coronary intervention (pPCI) remains a significant concern. Developing a predictive model of in-hospital mortality is crucial for identifying high-risk patients, guiding clinical decisions, and preventing in-hospital mortality. Machine learning (ML) may analyze patterns in large datasets and provide accurate predictions of in-hospital mortality in AMI patients following pPCI.
View Article and Find Full Text PDFMulticompartment Darcy Flow Model With Patient-Specific Parameterization: Effect of Heterogeneity and Anisotropy in Porous Parameters.
Int J Numer Method Biomed Eng
September 2025
School of Mathematics and Statistics, University of Glasgow, Glasgow, UK.
Blood perfusion in cardiac tissues involves intricate interactions among vascular networks and tissue mechanics. Perfusion deficit is one of the leading causes of cardiac diseases, and modeling certain cardiac conditions that are clinically infeasible, invasive, or costly can provide valuable supplementary insights to aid clinicians. However, existing homogeneous perfusion models lack the complexity required for patient-specific simulations.
View Article and Find Full Text PDFβ-blocker and clinical outcomes in patients after myocardial infarction: a systematic review and meta-analysis.
Eur J Clin Pharmacol
September 2025
Department of Forensic Pathology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Background And Objective: While current clinical guidelines generally advocate for beta-blocker therapy following acute myocardial infarction (AMI), conflicting findings have surfaced through large-scale observational studies and meta-analyses. We conducted this systematic review and meta-analysis of published observational studies to quantify the long-term therapeutic impact of beta-blocker across heterogeneous AMI populations.
Methods: We conducted comprehensive searches of the PubMed, Embase, Cochrane, and Web of Science databases for articles published from 2000 to 2025 that examine the link between beta-blocker therapy and clinical outcomes (last search update: March 1, 2025).